Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India.
Value Health Reg Issues. 2024 Jul;42:100991. doi: 10.1016/j.vhri.2024.100991. Epub 2024 May 8.
In recent years, newer drugs, such as ibrutinib, have shown promising improvements in the survival of patients with chronic lymphocytic leukemia (CLL). Despite their effectiveness, concerns about their cost have arisen, prompting the need for an evaluation of their cost-effectiveness. However, recent assessments of ibrutinib's cost-effectiveness for treating CLL in India reveal divergent conclusions. The discord centers on divergent cost-effectiveness thresholds, comparator regimens, cost calculations, and outcome valuation approaches. Such discrepancies affect public health decisions and patient care. The recommendation calls for adherence to methodological guidelines by future studies, fostering consistent findings to empower policy makers and clinicians in leveraging economic evidence for informed decision making in CLL treatment strategies.
近年来，新型药物，如伊布替尼，在改善慢性淋巴细胞白血病（CLL）患者的生存率方面显示出了有希望的改善。尽管这些药物具有疗效，但人们对其成本表示担忧，这促使我们需要对其成本效益进行评估。然而，最近对伊布替尼在印度治疗 CLL 的成本效益评估得出了不同的结论。这些分歧的核心在于成本效益阈值、对照方案、成本计算和结果评估方法的不同。这些差异会影响公共卫生决策和患者护理。该建议呼吁未来的研究遵循方法学准则，以产生一致的发现，使决策者和临床医生能够利用经济证据，为 CLL 治疗策略的决策提供信息。
